Vico Therapeutics Begins Twice‑Yearly Dosing of VO659 in Phase 1/2 Trial for Huntington’s Disease and Spinocerebellar Ataxias

As reported in Business Wire, Vico Therapeutics has initiated patient dosing in an expanded cohort of its Phase 1/2a clinical study evaluating VO659, an antisense oligonucleotide (ASO) designed to target…

Continue Reading Vico Therapeutics Begins Twice‑Yearly Dosing of VO659 in Phase 1/2 Trial for Huntington’s Disease and Spinocerebellar Ataxias

FDA Requests More Data on Vatiquinone for Friedreich Ataxia: What’s Next for PTC Therapeutics?

PTC Therapeutics announced that the US Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the company’s New Drug Application (NDA) for vatiquinone, an investigational therapy intended…

Continue Reading FDA Requests More Data on Vatiquinone for Friedreich Ataxia: What’s Next for PTC Therapeutics?
I Have a Rare Disease And I Am Crossing Borders
23/02/2016 Pics (C) Huw John, Cardiff. MANDATORY BYLINE - Huw John, Cardiff Alan Thomas from Llanboidy HealthWise Wales, a new project which will inform future generations’ NHS services, to help protect against fatal illnesses. e-mail: [email protected] Web: www.huwjohn.com

I Have a Rare Disease And I Am Crossing Borders

My name is Alan. I cross many borders as a person with a rare disease. These borders are physical, geographical and psychological. Crossing so many borders has earned me the…

Continue Reading I Have a Rare Disease And I Am Crossing Borders